January 27, 2011
US Army Study Shows STB Lifesaving Technology’sÂ® FASTÂ® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
ROCKVILLE, Md., Jan. 27, 2011 /PRNewswire/ -- In a study conducted jointly by the US Army Institute of Surgical Research and STB Lifesaving TechnologiesÃ®, and just published in The Journal of Trauma, STBÃ®'s FASTÃ® (Fibrin Adhesive STat) Dressing was shown to be superior to the most effective available agents for controlling severe arterial bleeding.
The study compared currently available agents with the FASTÃ® dressing, in a coagulopathic hemorrhage model simulating a gunshot wound to a major peripheral artery. The FASTÃ® dressing produced significantly better outcomes (higher survival rate, longer survival time, higher incidence of stable hemostasis and less blood loss). STBÃ®'s FASTÃ® dressing was the only agent that stopped bleeding and prevented exsanguination in most subjects.
"The consistently better results obtained using the FASTÃ® Dressing reflect the results of applying the unique FASTÃ® technology to this most challenging bleeding problem. The ability to optimally mix the fibrinogen and thrombin components during manufacture results in a hemostatic product of unprecedented effectiveness, flexibility and ease of handling. This technology is unaffected by the coagulation state of the patient and therefore functions when other types of products cannot. This has significant implications for the treatment of both military and civilian casualties," commented Dr. Martin MacPhee, STBÃ®'s Chief Scientific Officer.
The report emphasizes the urgent need for methods such as this to control hemorrhage in the field and operating rooms to potentially reduce war mortality, as uncontrolled bleeding remains the leading cause of potentially preventable death in combat casualties. Hemorrhage is also a leading cause of death in civilian trauma patients.
"Study after study has confirmed the faith we have in our product's ability to save lives, and it's why we refer to our technology as 'A Breakthrough for Life.' Test results such as this recent report demonstrate why the Army continues to support for our research, assisting us in accelerating the step-up to cGMP manufacturing, and the necessary work required to file for FDA approval to initiate human clinical trials," said Richard Moscarello, STBÃ®'s CEO.
Founded in 2005, STB Lifesaving TechnologiesÃ® (STBÃ®) is a privately held, pre-clinical stage, biotechnology development company located in Rockville, Maryland. STBÃ® is focused on developing a comprehensive suite of products to stop serious and life threatening bleeding in trauma and surgical settings. With a strong proprietary position using its all-natural, patented FASTÃ® technology platform, STBÃ®'s products will be indispensable to both the military and civilian medical markets.
SOURCE STB Lifesaving Technologies